7th In-House Impact: Biopharma Summit 2026

The 7th In-House Impact: Biopharma Summit is a premier event designed exclusively for senior in-house legal leaders within the biopharmaceutical industry. Organized by Hanson Wade, this summit provides a dedicated platform for General Counsels and Chief Legal Officers to navigate the complexities of 2026, including evolving FDA expectations, pricing reforms, geopolitical shifts, and the integration of AI into legal operations.

Key topics at the summit include strategies for managing FDA volatility, preparing for pricing reforms, designing responsible AI governance frameworks, safeguarding intellectual property and trade secrets, strengthening compliance maturity, anticipating cross-border risks, and improving deal readiness for partnerships, mergers and acquisitions, and IPO preparations. The agenda features over 15 strategic panel discussions and fireside chats led by more than 18 senior legal leaders from organizations such as Olema Oncology, Caribou Biosciences, Enveda Biosciences, Takeda Oncology, Legend Biotech, Boundless Bio, and Sionna Therapeutics.

Attendees can expect over eight hours of dedicated networking opportunities, including speed networking sessions and roundtable discussions, facilitating meaningful exchanges among peers. Notable speakers include Shawnte Mitchell, Chief Legal Officer & Corporate Secretary at Olema Oncology, and Jason Tejani, General Counsel & Corporate Secretary at Enveda Therapeutics, Inc. The event will be held at The Colonnade Hotel in Boston, Massachusetts, providing a conducive environment for learning and collaboration.

This summit is ideal for General Counsels, Chief Legal Officers, and senior in-house legal professionals within early-stage, growth-stage, and commercial biopharma organizations. It offers a unique opportunity to benchmark with peers, gain candid insights, and acquire practical strategies to address the pressing legal challenges of 2026.